BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16133689)

  • 1. Long-term effects on bone mineral density and bone metabolism of 6 months' treatment with gonadotropin-releasing hormone analogues in Japanese women: comparison of buserelin acetate with leuprolide acetate.
    Makita K; Ishitani K; Ohta H; Horiguchi F; Nozawa S
    J Bone Miner Metab; 2005; 23(5):389-94. PubMed ID: 16133689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of the change in bone mineral density induced by gonadotropin-releasing hormone agonist treatment for endometriosis.
    Matsuo H
    Fertil Steril; 2004 Jan; 81(1):149-53. PubMed ID: 14711558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone.
    Palomba S; Morelli M; Di Carlo C; Noia R; Pellicano M; Zullo F
    Fertil Steril; 2002 Jul; 78(1):63-8. PubMed ID: 12095492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
    Smith MR; McGovern FJ; Zietman AL; Fallon MA; Hayden DL; Schoenfeld DA; Kantoff PW; Finkelstein JS
    N Engl J Med; 2001 Sep; 345(13):948-55. PubMed ID: 11575286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density.
    Sagsveen M; Farmer JE; Prentice A; Breeze A
    Cochrane Database Syst Rev; 2003; 2003(4):CD001297. PubMed ID: 14583930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis.
    Divasta AD; Laufer MR; Gordon CM
    J Pediatr Adolesc Gynecol; 2007 Oct; 20(5):293-7. PubMed ID: 17868896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy.
    Ripps BA; VanGilder K; Minhas B; Welford M; Mamish Z
    J Reprod Med; 2003 Oct; 48(10):761-6. PubMed ID: 14619641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism.
    Palomba S; Orio F; Morelli M; Russo T; Pellicano M; Nappi C; Mastrantonio P; Lombardi G; Colao A; Zullo F
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4476-81. PubMed ID: 12364422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty.
    Boot AM; De Muinck Keizer-Schrama S; Pols HA; Krenning EP; Drop SL
    J Clin Endocrinol Metab; 1998 Feb; 83(2):370-3. PubMed ID: 9467543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial.
    DiVasta AD; Feldman HA; Sadler Gallagher J; Stokes NA; Laufer MR; Hornstein MD; Gordon CM
    Obstet Gynecol; 2015 Sep; 126(3):617-627. PubMed ID: 26181088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of gonadotropin-releasing hormone agonist on the bone mineral density of patients with endometriosis.
    Uemura T; Mohri J; Osada H; Suzuki N; Katagiri N; Minaguchi H
    Fertil Steril; 1994 Aug; 62(2):246-50. PubMed ID: 8034067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical trial of the effects of tibolone administered with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata.
    Palomba S; Affinito P; Tommaselli GA; Nappi C
    Fertil Steril; 1998 Jul; 70(1):111-8. PubMed ID: 9660431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A meta-analysis of preventing bone mineral loss in patients with endometriosis treated by gonadotrophin-releasing hormone analogues with add-back therapy].
    Niu ZR; Yue XJ; Kong QY; Wang YF; Yao YQ
    Zhonghua Fu Chan Ke Za Zhi; 2013 May; 48(5):338-43. PubMed ID: 24016475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of gonadotropin-releasing hormone agonists, nafarelin, buserelin, and leuprolide, on experimentally induced endometriosis in the rat.
    Mizutani T; Sakata M; Terakawa N
    Int J Fertil Menopausal Stud; 1995; 40(2):106-11. PubMed ID: 7599657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estriol add-back therapy in the long-acting gonadotropin-releasing hormone agonist treatment of uterine leiomyomata.
    Nakayama H; Yano T; Sagara Y; Kikuchi A; Ando K; Wang Y; Watanabe M; Matsumi H; Osuga Y; Momoeda M; Taketani Y
    Gynecol Endocrinol; 1999 Dec; 13(6):382-9. PubMed ID: 10685331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    Yonsei Med J; 2004 Aug; 45(4):676-82. PubMed ID: 15344210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women.
    Sienkiewicz E; Magkos F; Aronis KN; Brinkoetter M; Chamberland JP; Chou S; Arampatzi KM; Gao C; Koniaris A; Mantzoros CS
    Metabolism; 2011 Sep; 60(9):1211-21. PubMed ID: 21741057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy.
    van der Sluis IM; Boot AM; Krenning EP; Drop SL; de Muinck Keizer-Schrama SM
    J Clin Endocrinol Metab; 2002 Feb; 87(2):506-12. PubMed ID: 11836277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
    Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
    Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.